Current Status, Opportunities and Challenges of Rare Endocrine and Metabolic Diseases

WU Huixiao; LI Zongyue; XU Chao; ZHAO Jiajun

doi:10.12376/j.issn.2097-0501.2023.03.001

Journal of Rare Diseases > 2023 > 2(3): 319-324. > DOI: 10.12376/j.issn.2097-0501.2023.03.001

WU Huixiao, LI Zongyue, XU Chao, ZHAO Jiajun. Current Status, Opportunities and Challenges of Rare Endocrine and Metabolic Diseases[J]. Journal of Rare Diseases, 2023, 2(3): 319-324. DOI: 10.12376/j.issn.2097-0501.2023.03.001

Citation:

PDF (1147 KB)

Current Status, Opportunities and Challenges of Rare Endocrine and Metabolic Diseases

WU Huixiao^{1, 2, 3},
LI Zongyue^{1, 2, 3},
XU Chao^{1, 2, 3},
ZHAO Jiajun^{1, 2, 3, ,}

1.
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
2.
Shandong Key Laboratory of Endocrinology and Lipid Metabolism in Shandong Province, Jinan 250021, China
3.
Research Center of Stem Cell and Engineering Gene Therapy for Endocrine and Metabolic Diseases in Shandong Province, Jinan 250021, China

Funds:

National Natural Science Foundation of China 81974124

More Information

Corresponding author:
ZHAO Jiajun, E-mail: jjzhao@sdu.edu.cn
Received Date: June 10, 2023
Accepted Date: June 25, 2023

Graphical Abstract

Abstract

Abstract

The rare endocrine and metabolic diseases, due to their varieties, face many challenges in the study of clinical diagnosis, pathogenesis, and treatment. In the past a couple of years, the research on rare endocrine and metabolic diseases has been gradually improved. The diagnosis has made great progress. The research into molecular mechanism of rare endocrine and metabolic diseases has significantly advanced. The effort in exploring the breakthroughs and progress in therapeutic methods based on the pathogenesis of the diseases has also made. This article provides a brief overview of the current status of research into diagnosis, mechanism, and treatment of rare endocrine and metabolic diseases. In addition, the article points out the problems and challenges and proposes future possibilities.
- rare endocrine and metabolic diseases,
- diagnosis,
- mechanism,
- treatment

FullText(HTML)

References (31)

References

[1]	Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome[J]. Genome Med, 2022, 14(1): 23. doi: 10.1186/s13073-022-01026-w
[2]	Johnstone C, Hendry C, Farley A, et al. Endocrine system: part 1[J]. Nurs Stand, 2014, 28(38): 42-49. doi: 10.7748/ns.28.38.42.e7471
[3]	Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases[J]. NPJ Genom Med, 2018, 3: 16. doi: 10.1038/s41525-018-0053-8
[4]	Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing[J]. Proc Natl Acad Sci USA, 2009, 106(45): 19096-19101. doi: 10.1073/pnas.0910672106
[5]	Wu H, Shu M, Liu C, et al. Identification and characterization of novel carboxyl ester lipase gene variants in patients with different subtypes of diabetes[J]. BMJ Open Diabetes Res Care, 2023, 11(1): e003127. doi: 10.1136/bmjdrc-2022-003127
[6]	Wu H, Wang Y, Chen X, et al. Cell-dependent pathogenic roles of filamin B in different skeletal malformations[J]. Oxid Med Cell Longev, 2022, 2022: 8956636.
[7]	Wright CF, Quaife NM, Ramos-Hernández L, et al. Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms[J]. Am J Hum Genet, 2021, 108(6): 1083-1094. doi: 10.1016/j.ajhg.2021.04.025
[8]	Pan Q, Liu YJ, Bai XF, et al. VARAdb: a compreh-ensive variation annotation database for human[J]. Nucleic Acids Res, 2021, 49(D1): D1431-D1444. doi: 10.1093/nar/gkaa922
[9]	Zhang W, Zhang H, Yang H, et al. Computational resources associating diseases with genotypes, phenotypes and exposures[J]. Brief Bioinform, 2019, 20(6): 2098-2115. doi: 10.1093/bib/bby071
[10]	McNeill A. Good genotype-phenotype relationships in rare disease are hard to find[J]. Eur J Hum Genet, 2022, 30(3): 251. doi: 10.1038/s41431-022-01062-5
[11]	Agarwal SK, Impey S, McWeeney S, et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation[J]. Neoplasia, 2007, 9(2): 101-107. doi: 10.1593/neo.06706
[12]	Dreijerink KMA, Groner AC, Vos ESM, et al. Enhancer-mediated oncogenic function of the menin tumor suppressor in breast cancer[J]. Cell Rep, 2017, 18(10): 2359-2372. doi: 10.1016/j.celrep.2017.02.025
[13]	Brandi ML, Agarwal SK, Perrier ND, et al. Multiple endocrine neoplasia type 1: latest insights[J]. Endocr Rev, 2021, 42(2): 133-170. doi: 10.1210/endrev/bnaa031
[14]	El Hakam C, Parenté A, Baraige F, et al. PHEXL222P mutation increases phex expression in a new ENU mouse model for XLH disease[J]. Genes(Basel), 2022, 13(8): 1356.
[15]	Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment[J]. Curr Opin Pediatr, 2019, 31(6): 708-715. doi: 10.1097/MOP.0000000000000813
[16]	Li Z, Wu H, Wei S, et al. R158Q and G212S, novel pathogenic compound heterozygous variants in SLC12A3 of Gitelman syndrome[J]. Front Med, 2022, 16(6): 932-945. doi: 10.1007/s11684-022-0963-9
[17]	Tambuyzer E, Vandendriessche B, Austin CP, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead[J]. Nat Rev Drug Discov, 2020, 19(2): 93-111. doi: 10.1038/s41573-019-0049-9
[18]	Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial[J]. Lancet, 2019, 393(10189): 2416-2427. doi: 10.1016/S0140-6736(19)30654-3
[19]	Hughes DA, Gonzalez DE, Lukina EA, et al. Velagluce-rase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase Ⅲ clinical trials[J]. Am J Hematol, 2015, 90(7): 584-591. doi: 10.1002/ajh.24012
[20]	Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease(COMET): a phase 3, randomised, multicentre trial[J]. Lancet Neurol, 2021, 20(12): 1012-1026. doi: 10.1016/S1474-4422(21)00241-6
[21]	Brody H. Gene therapy[J]. Nature, 2018, 564(7735): S5. doi: 10.1038/d41586-018-07639-9
[22]	Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Cur-rent clinical applications of in vivo gene therapy with AAVs[J]. Mol Ther, 2021, 29(2): 464-488. doi: 10.1016/j.ymthe.2020.12.007
[23]	Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. doi: 10.1016/S0140-6736(17)31868-8
[24]	Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products[J]. EMBO Mol Med, 2017, 9(6): 737-740. doi: 10.15252/emmm.201707573
[25]	Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy(SMA)[J]. J Neurol, 2023, 270(5): 2531-2546. doi: 10.1007/s00415-023-11560-1
[26]	Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A[J]. N Engl J Med, 2022, 386(11): 1013-1025. doi: 10.1056/NEJMoa2113708
[27]	Hayashi Y, Sehara Y, Watano R, et al. Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in alpha-galactosidase A-deficient mice[J]. J Gene Med, 2023. doi: 10.1002/jgm.3560.
[28]	Hughes MP, Nelvagal HR, Coombe-Tennant O, et al. A novel small NPC1 promoter enhances AAV-mediated gene therapy in mouse models of niemann-pick type C1 disease[J]. Cells, 2023, 12(12): 1619. doi: 10.3390/cells12121619
[29]	Nan Z, Shekels L, Ryabinin O, et al. Intracerebroventri-cular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type Ⅰ(MPS-Ⅰ)[J]. Cell Transplant, 2012, 21(7): 1577-1593. doi: 10.3727/096368912X636894
[30]	Sinder BP, Novak S, Wee NKY, et al. Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype[J]. Stem Cells, 2020, 38(4): 530-541. doi: 10.1002/stem.3133
[31]	O'Brien SR, States LJ, Zhuang H. Neuroblastoma shown on ¹⁸F-DOPA PET/CT performed to evaluate congenital hyperinsulinism[J]. Clin Nucl Med, 2021, 46(11): 927-928. doi: 10.1097/RLU.0000000000003689

[1]	Hypothalamic and Pituitary Disease Group of China Alliance for Rare Diseases. Chinese Experts′ Consensus on the Management of Hypothalamic Obesity Secondary to Sellar Lesions[J]. Journal of Rare Diseases, 2024, 3(4): 479-491. DOI: 10.12376/j.issn.2097-0501.2024.04.011
[2]	JIAN Shan, WANG Changyan, ZHANG Caihui, SONG Hongmei. Renal Impairment Associated with Autoinflammatory Diseases[J]. Journal of Rare Diseases, 2024, 3(4): 423-430. DOI: 10.12376/j.issn.2097-0501.2024.04.003
[3]	ZHANG Xuanling, CHEN Chaoyang, WEI Ran, ZHOU Ying. Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders[J]. Journal of Rare Diseases, 2024, 3(2): 246-251. DOI: 10.12376/j.issn.2097-0501.2024.02.015
[4]	CHEN Yu, LI Jianwei, TAN Huiwen, YU Yerong. A Case Report of Marfan Syndrome with Pituitary Tumor Which Could be Misdiagnosed as Gigantism[J]. Journal of Rare Diseases, 2024, 3(2): 237-240. DOI: 10.12376/j.issn.2097-0501.2024.02.013
[5]	XING Mingquan, WU Weixia, SUN Xiaoxing, WANG Qikai, HAN Hao, GE Hongfeng. A Case of Senile Langerhans Cell Histiocytosis with Soft Tissue Mass as the Main Manifestation[J]. Journal of Rare Diseases, 2023, 2(3): 432-435. DOI: 10.12376/j.issn.2097-0501.2023.03.015
[6]	WANG Qian, SUN Quanya, HE Min, ZHANG Shuo, XIANG Boni, LI Qiufan, WANG Yong, ZHANG Xialing, DING Tianling, YE Hongying. Clinical Characteristics and Diagnostic Experience of Adult Thyroid Langerhans Cell Histiocytosis with Diabetes Insipidus[J]. Journal of Rare Diseases, 2023, 2(3): 346-352. DOI: 10.12376/j.issn.2097-0501.2023.03.005
[7]	WANG Rui, WANG Mingyue. A Case of Paraneoplastic Pemphigus with Malignant Thymoma and Obliterated Bronchiolitis[J]. Journal of Rare Diseases, 2023, 2(2): 256-260. DOI: 10.12376/j.issn.2097-0501.2023.02.011
[8]	ZHANG Yang, ZHANG Hexi, YAN Yan. A Case Report of Pericardial Mesothelioma Misdiagnosed as Tuberculous Pericarditis[J]. Journal of Rare Diseases, 2023, 2(1): 105-109. DOI: 10.12376/j.issn.2097-0501.2023.01.014
[9]	CAI Huacong, FENG Bin, CAO Wei, LIU Shufen, YUAN Tao, ZHANG Yan, LI Kuixing, ZHAO Yongqiang, WANG Shujie. A Young Hemophilia Patient with Advanced Hemophilic Arthritis and HIV Infection[J]. Journal of Rare Diseases, 2022, 1(4): 407-412. DOI: 10.12376/j.issn.2097-0501.2022.04.008
[10]	ZHAI Xiao, ZHU Huijuan. Progress in Diagnosis and Treatment of Autoimmune Hypophysitis[J]. Journal of Rare Diseases, 2022, 1(1): 45-50. DOI: 10.12376/j.issn.2097-0501.2022.01.008

Cited By

Cited by

Periodical cited type(7)

1.	唐凤敏，黄滔敏. 眼科玻璃体内注射药物的临床应用研究进展. 中国临床药学杂志. 2025(01): 71-76 .
2.	张磊，乐偲，刘岩，陈丽萌. 遗传性罕见肾脏病：精准肾脏病学的窗口. 罕见病研究. 2024(01): 1-11 . 本站查看
3.	北京大学医学部肾脏病学系专家组. 补体相关性肾病诊断和治疗专家共识. 中华内科杂志. 2024(03): 258-271 .
4.	邱婧妍，秘红岭. 依库珠单抗治疗阵发性睡眠性血红蛋白尿的研究进展. 医药前沿. 2024(03): 37-39+43 .
5.	刘爽，刘畅，江丹沁，苏畅，唐一楠. 重症肌无力治疗药物zilucoplan. 中国新药杂志. 2024(24): 2546-2549 .
6.	林颖，韩露，高圣乔，罗丹，肖智勇，周文霞. 基于转录组数据分析的六味地黄方活性组分LWD-b抗补体作用的发现与验证. 中国药理学与毒理学杂志. 2023(03): 168-177 .
7.	时念民，李林康，邵祝军，张文宏，吴疆，吕敏，郑佳音，陈直平，刘晓强，张宏，谭颖，刘小荣，赵明辉，罗哲，吕继成，路丽明. 补体相关性肾病人群中脑膜炎球菌疫苗和补体抑制剂联用的专家共识. 慢性病学杂志. 2023(08): 1156-1159 .

Other cited types(0)

Get Citation

PDF

XML

Article views PDF downloads Cited by(7)

Turn off MathJax

Article Contents

Abstract

References

Current Status, Opportunities and Challenges of Rare Endocrine and Metabolic Diseases

Abstract

References

Related Articles

Cited by

Periodical cited type(7)

Other cited types(0)

Catalog

Current Status, Opportunities and Challenges of Rare Endocrine and Metabolic Diseases

Abstract

References

Related Articles

Cited by

Periodical cited type(7)

Other cited types(0)

Catalog

Export File

Citation

Format

Content